Skip to main content
. 2016 Nov 21;129(9):1143–1154. doi: 10.1182/blood-2016-07-730648

Figure 4.

Figure 4.

Interaction with azole prophylaxis in AML17. (A) Azole vs not; (B) by type of azole; (C) survival in patients given concomitant GO and azoles. CR: complete remission; CRi: complete remission with incomplete peripheral count recovery; GO: gemtuzumab ozogamicin